Fasenra-话题@MedSci

#Fasenra#

10篇内容 | 1233人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1271175, encodeId=e61912e117505, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, objectTitle=FDA要求阿斯利康（AstraZeneca）提供更多关于的Fasenra治疗慢性鼻窦炎伴鼻息肉的数据, objectType=article, longId=300798, objectId=f582300e985d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f582300e985d, replyNumber=0, likeNumber=70, createdTime=2022-03-16, rootId=0, userName=zhangxingru, userId=bb0b97, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f582300e985d, moduleTitle=FDA要求阿斯利康（AstraZeneca）提供更多关于的Fasenra治疗慢性鼻窦炎伴鼻息肉的数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f582300e985d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271174, encodeId=c9ee12e11740e, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, objectTitle=FDA授予IL-5抑制剂Fasenra（贝那利珠单抗）快速通道资格，用于治疗嗜酸性粒细胞性胃炎（EG）, objectType=article, longId=220145, objectId=3588220145b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3588220145b0, replyNumber=0, likeNumber=39, createdTime=2021-11-13, rootId=0, userName=zhangxingru, userId=bb0b97, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3588220145b0, moduleTitle=FDA授予IL-5抑制剂Fasenra（贝那利珠单抗）快速通道资格，用于治疗嗜酸性粒细胞性胃炎（EG）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3588220145b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271173, encodeId=3d5912e11731c, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, objectTitle=哮喘治疗新突破：IL-15Rα单抗FASENRA让62%的患者摆脱口服糖皮质激素, objectType=article, longId=202761, objectId=152c202e61d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=152c202e61d8, replyNumber=0, likeNumber=33, createdTime=2020-11-03, rootId=0, userName=zhangxingru, userId=bb0b97, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=152c202e61d8, moduleTitle=哮喘治疗新突破：IL-15Rα单抗FASENRA让62%的患者摆脱口服糖皮质激素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=152c202e61d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271172, encodeId=5e9512e117230, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, objectTitle=阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效, objectType=article, longId=198911, objectId=81e1198911ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81e1198911ce, replyNumber=0, likeNumber=41, createdTime=2020-08-08, rootId=0, userName=zhangxingru, userId=bb0b97, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81e1198911ce, moduleTitle=阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81e1198911ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271171, encodeId=c51b12e1171d1, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, objectTitle=FDA批准预填充自动注射器Fasenra治疗哮喘, objectType=article, longId=180546, objectId=25eb180546e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25eb180546e0, replyNumber=0, likeNumber=45, createdTime=2019-10-07, rootId=0, userName=zhangxingru, userId=bb0b97, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25eb180546e0, moduleTitle=FDA批准预填充自动注射器Fasenra治疗哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25eb180546e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271170, encodeId=113812e1170b0, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, objectTitle=嗜酸性粒细胞性食管炎：Fasenra被FDA授予孤儿药物资格, objectType=article, longId=178352, objectId=af411e83525b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af411e83525b, replyNumber=0, likeNumber=35, createdTime=2019-08-30, rootId=0, userName=zhangxingru, userId=bb0b97, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af411e83525b, moduleTitle=嗜酸性粒细胞性食管炎：Fasenra被FDA授予孤儿药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af411e83525b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271169, encodeId=07fd12e116966, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, objectTitle=NEJM：Fasenra符合嗜酸性粒细胞增多症中期研究的主要目标, objectType=article, longId=163719, objectId=9576163e19da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9576163e19da, replyNumber=0, likeNumber=41, createdTime=2019-04-07, rootId=0, userName=zhangxingru, userId=bb0b97, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9576163e19da, moduleTitle=NEJM：Fasenra符合嗜酸性粒细胞增多症中期研究的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9576163e19da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271168, encodeId=62da12e1168e3, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, objectTitle=BORA III期延展试验证明阿斯利康IL-5单抗Fasenra对严重哮喘具有长期疗效, objectType=article, longId=149082, objectId=636f14908287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=636f14908287, replyNumber=0, likeNumber=31, createdTime=2018-09-20, rootId=0, userName=zhangxingru, userId=bb0b97, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=636f14908287, moduleTitle=BORA III期延展试验证明阿斯利康IL-5单抗Fasenra对严重哮喘具有长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=636f14908287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271167, encodeId=778912e116713, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, objectTitle=阿斯利康的Fasenra未达到晚期COPD研究的主要目标, objectType=article, longId=138002, objectId=a79113800294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a79113800294, replyNumber=0, likeNumber=31, createdTime=2018-05-14, rootId=0, userName=zhangxingru, userId=bb0b97, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a79113800294, moduleTitle=阿斯利康的Fasenra未达到晚期COPD研究的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a79113800294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271166, encodeId=04c212e1166d7, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, objectTitle=欧盟批准AZ的Fasenra治疗严重哮喘, objectType=article, longId=126316, objectId=730b1263163a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=730b1263163a, replyNumber=0, likeNumber=37, createdTime=2018-01-13, rootId=0, userName=zhangxingru, userId=bb0b97, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=730b1263163a, moduleTitle=欧盟批准AZ的Fasenra治疗严重哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=730b1263163a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Fasenra

2020-05-29

zhangxingru (审核中...)

前往app查看评论内容

#Fasenra#

FDA要求阿斯利康（AstraZeneca）提供更多关于的Fasenra治疗慢性鼻窦炎伴鼻息肉的数据

2022-03-16

zhangxingru (审核中...)

前往app查看评论内容

#Fasenra#

FDA授予IL-5抑制剂Fasenra（贝那利珠单抗）快速通道资格，用于治疗嗜酸性粒细胞性胃炎（EG）

2021-11-13

zhangxingru (审核中...)

前往app查看评论内容

#Fasenra#

哮喘治疗新突破：IL-15Rα单抗FASENRA让62%的患者摆脱口服糖皮质激素

2020-11-03

zhangxingru (审核中...)

前往app查看评论内容

#Fasenra#

阿斯利康的IL-5受体单抗Fasenra：III期临床证实在嗜酸性哮喘中具有强大疗效

2020-08-08

zhangxingru (审核中...)

前往app查看评论内容

#Fasenra#

FDA批准预填充自动注射器Fasenra治疗哮喘

2019-10-07

zhangxingru (审核中...)

前往app查看评论内容

#Fasenra#

嗜酸性粒细胞性食管炎：Fasenra被FDA授予孤儿药物资格

2019-08-30

zhangxingru (审核中...)

前往app查看评论内容

#Fasenra#

NEJM：Fasenra符合嗜酸性粒细胞增多症中期研究的主要目标

2019-04-07

zhangxingru (审核中...)

前往app查看评论内容

#Fasenra#

BORA III期延展试验证明阿斯利康IL-5单抗Fasenra对严重哮喘具有长期疗效

2018-09-20

zhangxingru (审核中...)

前往app查看评论内容

#Fasenra#

阿斯利康的Fasenra未达到晚期COPD研究的主要目标

2018-05-14

zhangxingru (审核中...)

前往app查看评论内容

#Fasenra#

欧盟批准AZ的Fasenra治疗严重哮喘

2018-01-13

科室
- - 订阅+
  - 更多科室
工具
服务